CASI Pharmaceuticals executed an Assignment Agreement with Cleave Therapeutics, Inc., under which CASI obtained all rights and global intellectual property related to CB-5339, a novel VCP/p97 inhibitor, as well as all remaining CB-5339 drug substance and drug product. Additionally, CASI will assume responsibility of the CB-5339 Investigational New Drug application. CB-5339 is an oral, second-generation, small molecule valosin-containing protein (VCP)/p97 inhibitor, designed to disrupt protein...